Discrimination of Diabetes Mellitus Patients and Healthy Individuals Based on Volatile Organic Compounds (VOCs): Analysis of Exhaled Breath and Urine Samples by Using E-Nose and VE-Tongue

Identificador:  imarina:9325524

Handle: https://hdl.handle.net/20.500.11797/imarina9325524

Autors:  Zaim, O; Bouchikhi, B; Motia, S; Abelló, S; Llobet, E; El Bari, N

Resum:
Studies suggest that breath and urine analysis can be viable non-invasive methods for diabetes management, with the potential for disease diagnosis. In the present work, we employed two sensing strategies. The first strategy involved analyzing volatile organic compounds (VOCs) in biological matrices, such as exhaled breath and urine samples collected from patients with diabetes mellitus (DM) and healthy controls (HC). The second strategy focused on discriminating between two types of DM, related to type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), by using a data fusion method. For this purpose, an electronic nose (e-nose) based on five tin oxide (SnO2) gas sensors was employed to characterize the overall composition of the collected breath samples. Furthermore, a voltametric electronic tongue (VE-tongue), composed of five working electrodes, was dedicated to the analysis of urinary VOCs using cyclic voltammetry as a measurement technique. To evaluate the diagnostic performance of the electronic sensing systems, algorithm tools including principal component analysis (PCA), discriminant function analysis (DFA) and receiver operating characteristics (ROC) were utilized. The results showed that the e-nose and VE-tongue could discriminate between breath and urine samples from patients with DM and HC with a success rate of 99.44% and 99.16%, respectively. However, discrimination between T1DM and T2DM samples using these systems alone was not perfect. Therefore, a data fusion method was proposed as a goal to overcome this shortcoming. The fusing of data from the two instruments resulted in an enhanced success rate of classification (i.e., 93.75% for the recognition of T1DM and T2DM).